Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crestor Patent Settlement Allows Actavis Generic Entry In May 2016

This article was originally published in The Pink Sheet Daily

Executive Summary

The agreement permits Actavis to launch its generic version of AstraZeneca’s Crestor 67 days before the patent on the cholesterol-lowering drug expires in return for paying AstraZeneca 39% of its net sales during this period; Actavis may also launch its alternative zinc salt formulation of Crestor at the same time.

Advertisement

Related Content

Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Keeping Track: FDA Approves Briviact, Refuses To File Firdapse, Rejects Remune
FDA's NDA And BLA Approvals
Korea’s Hanmi Hopes U.S. Esomeprazole Launch Will Counter Disappointing China Results
AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel